Results 31 to 40 of about 467,609 (357)

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations

Haematologica, 2014
Somatic mutations of TET2, IDH1, and IDH2 have been described in myelodysplastic syndrome. The impact of these mutations on outcome of myelodysplastic syndrome and their progression to secondary acute myeloid leukemia remains unclear.
Tung-Liang Lin, Yasunobu Nagata, Hsiao-Wen Kao, Masashi Sanada, Yusuke Okuno, Chein-Fuang Huang, Der-Cherng Liang, Ming-Chung Kuo, Chang-Liang Lai, En-Hui Lee, Yu-Shu Shih, Hiroko Tanaka, Yuichi Shiraishi, Kenichi Chiba, Tung-Huei Lin, Jin-Hou Wu, Satoru Miyano, Seishi Ogawa, Lee-Yung Shih   +18 more
doaj   +1 more source

Analogue peptides for the immunotherapy of human acute myeloid leukemia [PDF]

, 2015
Accepted manuscript. The final publication is available at: http://link.springer.com/article/10.1007%2Fs00262-015-1762-9The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials.
A Driessche Van, A Gros, A Scardino, A Serrano, A Sevko, A Snyder, A Tsuboi, AB Bakker, Aleksandrs Malinovskis, Andrew Mead, AT Cheuk, AW Purcell, B Engels, B Falini, B Maecker, B Maecker, B Uttenthal, BA Guinn, BA Guinn, Barbara-ann Guinn, C Chaise, C Maccalli, CL Slingluff Jr, D Cilloni, D Mason, DA Gross, DE Speiser, DH Chang, DJ Schwartzentruber, E Estey, E Romano, F Ghiringhelli, FS Hodi, G Khan, H Kobayashi, H Ohminami, HJ Kolb, HJ Stauss, I Bellantuono, J Bae, J Bae, J Fourcade, J Greiner, J Greiner, J Kronke, J Pinilla-Ibarz, J Pinilla-Ibarz, JH Sampson, JJ Molldrem, JL Chen, JL Chen, JN Kochenderfer, JS Ko, JW Wells, K Inoue, K Inoue, K Rezvani, K Rezvani, KM Zirlik, L Chan, L Fong, L Gao, LV Ly, M Harndahl, M Kapp, M Subklewe, MA Cheever, MG Warnock, MM Gubin, MR Parkhurst, MS Bijker, N Hardwick, Nicola R. Hardwick, O Christensen, O Hamid, P Brossart, P Bruggen van der, P Keskinen, PG Maslak, PG Maslak, R Cibotti, RA Padua, RF Schlenk, RJ May, S Frankild, S Hofmann, S Narayan, S Ochsenreither, S Pascolo, S Suekane, S Walter, SH Burg van der, SK Singh, SL Topalian, SP Adams, Susanne Hofmann, T Lovgren, U Keilholz, U Sahin, V Bhardwaj, WS Meng, Y Oka, Z Trajanoski   +102 more
core   +2 more sources

Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells

Haematologica, 2018
Acute myeloid leukemia is a disorder characterized by abnormal differentiation of myeloid cells and a clonal proliferation derived from primitive hematopoietic stem cells.
Dang Wu, Wanyan Wang, Wuyan Chen, Fulin Lian, Li Lang, Ying Huang, Yechun Xu, Naixia Zhang, Yinbin Chen, Mingyao Liu, Ruth Nussinov, Feixiong Cheng, Weiqiang Lu, Jin Huang   +13 more
doaj   +1 more source

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]

, 2014
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin, Blatt, Katharina, Cerny-Reiterer, Sabine, Herndlhofer, Susanne, Herrmann, Harald, Hoermann, Grego, Holyoake, Tessa L., Mannhalter, Christine, Mayerhofer, Matthias, Rulicke, Thomas, Sadovnik, Irina, Sperr, Wolfgang R., Stefanzl, Gabriele, Streubel, Berthold, Valent, Peter, Willmann, Michael   +15 more
core   +1 more source

t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients

Haematologica, 2014
Acute myeloid leukemia with t(6;9)(p22;q34) is listed as a distinct entity in the 2008 World Health Organization classification, but little is known about the clinical implications of t(6;9)-positive myeloid leukemia in children.
Julie Damgaard Sandahl, Eva A. Coenen, Erik Forestier, Jochen Harbott, Bertil Johansson, Gitte Kerndrup, Souichi Adachi, Anne Auvrignon, H. Berna Beverloo, Jean-Michel Cayuela, Lucy Chilton, Maarten Fornerod, Valérie de Haas, Christine J. Harrison, Hiroto Inaba, Gertjan J.L. Kaspers, Der-Cherng Liang, Franco Locatelli, Riccardo Masetti, Christine Perot, Susana C. Raimondi, Katarina Reinhardt, Daisuke Tomizawa, Nils von Neuhoff, Marco Zecca, C. Michel Zwaan, Marry M. van den Heuvel-Eibrink, Henrik Hasle   +27 more
doaj   +1 more source

Biological aspects of mTOR in leukemia [PDF]

, 2018
The mammalian target of rapamycin (mTOR) is a central processor of intra-and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival.
Bianchi, Mp, Gianfelici, V, Mirabilii, S, Piedimonte, M, Ricciardi, Mr, Tafuri, A.   +5 more
core   +1 more source

Myeloid sarcoma as a manifestation of acute myeloid leukemia

Baylor University Medical Center Proceedings, 2021
We report a case of a 43-year-old man who presented with dyspnea because of large bilateral pleural effusions and imaging findings of a large periaortic mass with compression of the esophagus and left atrium. Subsequent soft tissue biopsy was consistent with myeloid sarcoma, and bone marrow biopsy was consistent with acute myeloid leukemia.
Lewis Woods, Jerry Fan, Hameed Ali
openaire   +3 more sources

One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia

Frontiers in Immunology, 2022
Acute myeloid leukemia is the most common acute leukemia in adults, with accumulation of abundant blasts and impairment of hematogenic function. Despite great advances in diagnosis and therapy, the overall survival of patients with acute myeloid leukemia
Xianfeng Ouyang, Xianfeng Ouyang, Yuping Gong   +2 more
doaj   +1 more source

Anterior myeloid sarcoma revealing acute myeloid leukemia: Case report

Egyptian Journal of Chest Disease and Tuberculosis, 2016
Myeloid sarcoma (MS) is a tumor mass of myeloblasts or immature myeloid cells occurring in an extramedullary site or in the bone and generally precedes or reveals myeloid leukemia. It rarely occurs in the mediastinum.
H. Slimani, L. Achaachi, Y. Benbaba, L. Herrak, K. Znati, M. Ftouh   +5 more
doaj   +1 more source

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients [PDF]

, 2018
open25noSecond-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients ...

core   +1 more source